1. Home
  2. GANX vs JUNE Comparison

GANX vs JUNE Comparison

Compare GANX & JUNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • JUNE
  • Stock Information
  • Founded
  • GANX 2017
  • JUNE 1998
  • Country
  • GANX United States
  • JUNE Singapore
  • Employees
  • GANX N/A
  • JUNE N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • JUNE
  • Sector
  • GANX Health Care
  • JUNE
  • Exchange
  • GANX Nasdaq
  • JUNE Nasdaq
  • Market Cap
  • GANX 41.9M
  • JUNE 45.8M
  • IPO Year
  • GANX 2021
  • JUNE 2024
  • Fundamental
  • Price
  • GANX $2.28
  • JUNE $3.85
  • Analyst Decision
  • GANX Strong Buy
  • JUNE
  • Analyst Count
  • GANX 5
  • JUNE 0
  • Target Price
  • GANX $7.60
  • JUNE N/A
  • AVG Volume (30 Days)
  • GANX 264.8K
  • JUNE 23.4K
  • Earning Date
  • GANX 11-14-2024
  • JUNE 11-07-2024
  • Dividend Yield
  • GANX N/A
  • JUNE N/A
  • EPS Growth
  • GANX N/A
  • JUNE N/A
  • EPS
  • GANX N/A
  • JUNE N/A
  • Revenue
  • GANX N/A
  • JUNE $2,903,179.00
  • Revenue This Year
  • GANX N/A
  • JUNE N/A
  • Revenue Next Year
  • GANX N/A
  • JUNE N/A
  • P/E Ratio
  • GANX N/A
  • JUNE N/A
  • Revenue Growth
  • GANX N/A
  • JUNE N/A
  • 52 Week Low
  • GANX $0.89
  • JUNE $2.75
  • 52 Week High
  • GANX $5.33
  • JUNE $5.97
  • Technical
  • Relative Strength Index (RSI)
  • GANX 57.43
  • JUNE N/A
  • Support Level
  • GANX $2.06
  • JUNE N/A
  • Resistance Level
  • GANX $2.65
  • JUNE N/A
  • Average True Range (ATR)
  • GANX 0.29
  • JUNE 0.00
  • MACD
  • GANX 0.01
  • JUNE 0.00
  • Stochastic Oscillator
  • GANX 66.36
  • JUNE 0.00

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

About JUNE Junee Limited Ordinary Shares

Junee Ltd is a holding company that operates through its subsidiary. It is engaged in providing design, fit-out, repair, and maintenance services for commercial and residential buildings. The design services include both the consultation with its staff and the actual design work. Fit-out works include installing protective materials to cover floors or walls, installing or constructing partition walls, installing switches, power outlets, telephone wiring, computer outlet covers, and other electrical and wiring works. Repair and maintenance works include, among other things, replacement of fixtures and fittings, repair and maintenance of cupboards and shelves, and repainting walls and ceilings. Geographically, the company derives all of its revenue from its customers in Hong Kong.

Share on Social Networks: